Drugmaker pauses HPV Gardasil exports as rival Pfizer gets boost from better than expected Covid vaccine and pill sales ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

Warren asked him to pledge not to receive any compensation from lawsuits against pharma companies as HHS secretary and four ...

RAHWAY, N.J., February 04, 2025 -- ( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter of 2024.

"While many of them have been in the market over a long time, some players like MSD have re-entered the ... market has seen launches like Mercks’ Gardasil and GSK’s Cervarix which are under ...

President Donald Trump’s pick for secretary of Health and Human Services said he will divest his interest in lawsuits against an HPV vaccine manufacturer. In written responses to questions from Sen.

Kennedy Jr., President Trump’s nominee to run the Department of Health and Human Services, is giving away the fees that he could earn from litigation over Merck’s HPV vaccine Gardasil — to ...

Kennedy Jr. told lawmakers in response to questions released on Friday that he would divest his interest in litigation against a major HPV vaccine maker and would sign over the financial stake to ...

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused ...

GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1 ...

That included an arrangement with a law firm that's sued Merck over Gardasil, its human papillomavirus vaccine that prevents cervical cancer. The deal earned Kennedy $850,000 last year ...

RFK Jr. Says He'll Stop Collecting Fees From HPV Vaccine Lawsuit, but Other Ethics Questions Remain WASHINGTON (AP) — Facing intense scrutiny from senators over his potential profit from vaccine ...